198 related articles for article (PubMed ID: 33798547)
21. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Chen YL; Wang GX; Lin BA; Huang JS
Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p.
Zhou WY; Zhang MM; Liu C; Kang Y; Wang JO; Yang XH
J Cell Physiol; 2019 Dec; 234(12):23176-23189. PubMed ID: 31206665
[TBL] [Abstract][Full Text] [Related]
23. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR-363-3p.
Rong H; Chen B; Wei X; Peng J; Ma K; Duan S; He J
Thorac Cancer; 2020 Mar; 11(3):659-671. PubMed ID: 31968395
[TBL] [Abstract][Full Text] [Related]
25. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
26. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; Roden AC; Hirsch FR; Wistuba II; Pusztai L
Breast Cancer Res; 2019 Jun; 21(1):72. PubMed ID: 31196152
[TBL] [Abstract][Full Text] [Related]
27. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
28. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
29. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer.
Mekky RY; Ragab MF; Manie T; Attia AA; Youness RA
Transl Oncol; 2023 May; 31():101653. PubMed ID: 36907052
[TBL] [Abstract][Full Text] [Related]
30. XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.
Salama EA; Adbeltawab RE; El Tayebi HM
Front Oncol; 2019; 9():1459. PubMed ID: 31998636
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma.
Liu Y; Chang Y; Cai YX
Reprod Sci; 2020 Oct; 27(10):1848-1856. PubMed ID: 32748220
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of MiR-146a-5p Upregulates lncRNA HOTAIR in Triple-Negative Breast Cancer Cells and Predicts Poor Prognosis.
Liang H; Huang W; Wang Y; Ding L; Zeng L
Technol Cancer Res Treat; 2019; 18():1533033819882949. PubMed ID: 31672084
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoints in aggressive breast cancer subtypes.
Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
35. The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p.
Wang H; Shen Q; Zhang X; Yang C; Cui S; Sun Y; Wang L; Fan X; Xu S
Cell Physiol Biochem; 2017; 41(6):2221-2229. PubMed ID: 28448993
[TBL] [Abstract][Full Text] [Related]
36. Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression.
Hajibabaei S; Sotoodehnejadnematalahi F; Nafissi N; Zeinali S; Azizi M
Sci Rep; 2023 Jan; 13(1):1003. PubMed ID: 36653507
[TBL] [Abstract][Full Text] [Related]
37. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
Li D; Wang X; Yang M; Kan Q; Duan Z
Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483
[TBL] [Abstract][Full Text] [Related]
38. LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer.
Zhang W; Xin J; Lai J; Zhang W
Immunobiology; 2022 Jan; 227(1):152163. PubMed ID: 34896914
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
